Overview

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patie

Status:
Completed

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the pharmacokinetic profile of TMC125 400mg with tenofovir DF/emtricitabine FDC (fixed dose combination) 300/200mg all dosed once daily with and without darunavir/ritonavir 800/100 mg once daily in HIV-1 infected, antiretroviral (ARV) naÃ-ve patients (patients who have never received ARV treatment).

Phase:

Phase 2

Details

Lead Sponsor:

Tibotec, Inc

Collaborator:

Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Treatments:

Darunavir
Emtricitabine
Etravirine
Ritonavir
Tenofovir